Personalized after-surgery treatment for endometrial cancer by tumor type
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies which after-surgery (adjuvant) treatment works best when endometrial cancer is classified by specific tumor DNA/molecular features. You may be offered treatment based on the tumor results, aiming to improve outcomes and lower the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer that has been confirmed by pathology, and you had surgery to remove the uterus and both ovaries/tubes
- Your tumor must have a complete molecular test result done using the WHO 2020 classification method
- Your scans (CT or whole-body PET-CT) show no spread to distant organs
- You should be able to start planned after-surgery treatment within 10 weeks of surgery and attend follow-up visits
- You must have an overall health score (WHO performance status) of 0, 1, or 2
- You must not have had pelvic radiation before the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using tumor “molecular” results plus standard risk factors can guide the best type and timing of radiation after surgery for early-stage endometrial cancer. It may help you avoid under- or overtreatment by matching radiotherapy to your specific risk.
This trial tests whether taking a daily pill called olaparib after standard chemoradiation can help prevent endometrial cancer with a p53 mutation from coming back. Half of participants will receive olaparib, and the other half will just be watched closely.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial tests a precise type of radiation (stereotactic radiotherapy) given after surgery for endometrial cancer. It aims to improve treatment while reducing side effects.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.